Product Introduction
Sunitinib Malate (CAS: 341031-54-7) serves as a specialized synthesis intermediate and building block designed for process development and lab-scale research. It is a critical starting material for evaluating downstream chemical reactions and preparing reference standards in multi-kinase studies. We maintain strict control over impurity levels to guarantee high batch consistency, with detailed COA and MSDS available for thorough purity review. In application, this yellow-orange powder offers reliable solubility in DMSO and predictable thermal stability during organic synthesis. Proper storage requires keeping the material sealed in light-resistant containers below 25°C to preserve its chemical integrity. Please verify local compliance before commercial sourcing.
CAS:341031-54-7
Properties: Yellow to orange-yellow crystalline powder; odorless; hygroscopic.
Solubility: Soluble in dimethyl sulfoxide and methanol 、Slightly soluble in water and ethanol 、Almost insoluble in n-hexane and ether
Melting point: 174–176°C
Purpose: Multitarget receptor tyrosine kinase inhibitor For advanced renal cell carcinoma, gastrointestinal stromal tumors, pancreatic neuroendocrine tumors, etc.
Storage conditions: Store in a sealed container, protected from light, in a dry and cool place at refrigeration temperature (2–8°C); keep moisture-proof, light-resistant, and sealed away from oxidizing agents.
Product Characteristics
- Multi-Targeted Inhibition: It simultaneously blocks multiple receptors, including VEGFR, PDGFR, KIT, and FLT3.
- Dual Anti-Cancer Mechanism: It cuts off the blood and nutrient supply to tumors while directly stopping cancer cell growth.
- Oral Convenience: Its capsule form makes administration easy. Patients do not need long hospital stays for intravenous infusions.
- High Precision: It targets cancer cells specifically, causing less harm to normal healthy cells.
Product Uses
- Renal Cell Carcinoma (RCC) Treatment: It serves as a first-line standard therapy for advanced or metastatic kidney cancer.
- Gastrointestinal Stromal Tumor (GIST) Treatment: It treats GIST patients whose disease progressed on imatinib, or who cannot tolerate imatinib.
- Pancreatic Neuroendocrine Tumors (pNET) Treatment: It treats progressive, unresectable, or metastatic pNET. It significantly extends progression-free survival.
Application Scenarios
- Oncology Core Prescriptions: Oncologists widely prescribe it as a cornerstone treatment for specific solid tumors, especially in drug-resistant cases.
- Generic Drug Formulation: Pharmaceutical manufacturers purchase this Active Pharmaceutical Ingredient (API) to develop generic capsules and conduct bioequivalence studies.
- Combination Therapy Research: Researchers use it in combination trials with immunotherapy (such as PD-1 inhibitors) to boost anti-cancer efficacy.
